Viatris Gross Profit 2012-2025 | VTRS
Viatris annual/quarterly gross profit history and growth rate from 2012 to 2025. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Viatris gross profit for the quarter ending September 30, 2025 was $1.372B, a 6.01% decline year-over-year.
- Viatris gross profit for the twelve months ending September 30, 2025 was $5.081B, a 15.4% decline year-over-year.
- Viatris annual gross profit for 2024 was $5.624B, a 12.66% decline from 2023.
- Viatris annual gross profit for 2023 was $6.439B, a 0.9% decline from 2022.
- Viatris annual gross profit for 2022 was $6.497B, a 16.53% increase from 2021.
|
Viatris Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2024 | $5,624 |
| 2023 | $6,439 |
| 2022 | $6,497 |
| 2021 | $5,576 |
| 2020 | $3,797 |
| 2019 | $3,898 |
| 2018 | $4,002 |
| 2017 | $4,783 |
| 2016 | $4,697 |
| 2015 | $4,216 |
| 2014 | $3,528 |
| 2013 | $3,040 |
| 2012 | $2,908 |
| 2011 | $2,563 |
|
Viatris Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2025-09-30 | $1,372 |
| 2025-06-30 | $1,333 |
| 2025-03-31 | $1,161 |
| 2024-12-31 | $1,215 |
| 2024-09-30 | $1,459 |
| 2024-06-30 | $1,445 |
| 2024-03-31 | $1,504 |
| 2023-12-31 | $1,597 |
| 2023-09-30 | $1,691 |
| 2023-06-30 | $1,609 |
| 2023-03-31 | $1,542 |
| 2022-12-31 | $1,274 |
| 2022-09-30 | $1,748 |
| 2022-06-30 | $1,703 |
| 2022-03-31 | $1,771 |
| 2021-12-31 | $1,546 |
| 2021-09-30 | $1,574 |
| 2021-06-30 | $1,328 |
| 2021-03-31 | $1,127 |
| 2020-12-31 | $706 |
| 2020-09-30 | $1,159 |
| 2020-06-30 | $1,026 |
| 2020-03-31 | $906 |
| 2019-12-31 | $1,087 |
| 2019-09-30 | $1,072 |
| 2019-06-30 | $933 |
| 2019-03-31 | $805 |
| 2018-12-31 | $1,016 |
| 2018-09-30 | $1,039 |
| 2018-06-30 | $963 |
| 2018-03-31 | $984 |
| 2017-12-31 | $1,295 |
| 2017-09-30 | $1,178 |
| 2017-06-30 | $1,225 |
| 2017-03-31 | $1,085 |
| 2016-12-31 | $1,335 |
| 2016-09-30 | $1,283 |
| 2016-06-30 | $1,172 |
| 2016-03-31 | $907 |
| 2015-12-31 | $1,063 |
| 2015-09-30 | $1,315 |
| 2015-06-30 | $1,008 |
| 2015-03-31 | $830 |
| 2014-12-31 | $969 |
| 2014-09-30 | $1,012 |
| 2014-06-30 | $809 |
| 2014-03-31 | $738 |
| 2013-12-31 | $796 |
| 2013-09-30 | $809 |
| 2013-06-30 | $742 |
| 2013-03-31 | $694 |
| 2012-12-31 | $742 |
| 2012-09-30 | $793 |
| 2012-06-30 | $703 |
| 2012-03-31 | $670 |
| 2011-12-31 | $645 |
| 2011-09-30 | $658 |
| 2011-06-30 | $669 |
| 2011-03-31 | $591 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $18.163B | $14.739B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $150.156B | 27.25 |
| HCA Healthcare (HCA) | United States | $120.821B | 19.12 |
| CVS Health (CVS) | United States | $99.843B | 11.63 |
| Elevance Health (ELV) | United States | $76.540B | 11.49 |
| Cencora (COR) | United States | $70.193B | 22.08 |
| Natera (NTRA) | United States | $28.526B | 0.00 |
| Labcorp Holdings (LH) | United States | $23.430B | 17.86 |
| DiDi Global (DIDIY) | China | $21.650B | 20.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $15.306B | 0.00 |
| BioMerieux (BMXMF) | France | $13.324B | 0.00 |
| Solventum (SOLV) | United States | $13.104B | 12.72 |
| Medpace Holdings (MEDP) | United States | $12.148B | 27.98 |
| Revvity (RVTY) | United States | $10.887B | 18.94 |
| CochLear (CHEOY) | Australia | $9.243B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.941B | 15.29 |
| ICON (ICLR) | Ireland | $7.510B | 7.45 |
| Sonic Healthcare (SKHHY) | Australia | $7.449B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $7.008B | 41.78 |
| HealthEquity (HQY) | United States | $6.312B | 23.60 |
| Avantor (AVTR) | United States | $6.275B | 10.11 |
| Bausch + Lomb (BLCO) | Canada | $6.034B | 39.60 |
| PACS (PACS) | United States | $5.922B | 36.01 |
| Caris Life Sciences,�Inc (CAI) | United States | $5.818B | 0.00 |
| Sotera Health (SHC) | United States | $4.864B | 23.45 |
| Alignment Healthcare (ALHC) | United States | $4.040B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $3.532B | 20.61 |
| Concentras Parent (CON) | United States | $3.017B | 18.83 |
| GeneDx Holdings (WGS) | United States | $2.606B | 45.76 |
| Establishment Labs Holdings (ESTA) | United States | $2.168B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.000B | 25.77 |
| Organon (OGN) | United States | $1.921B | 2.15 |
| Pediatrix Medical (MD) | United States | $1.848B | 11.04 |
| Progyny (PGNY) | United States | $1.784B | 35.07 |
| Ardent Health (ARDT) | United States | $1.375B | 4.49 |
| InnovAge Holding (INNV) | United States | $1.134B | 167.20 |
| CareDx (CDNA) | United States | $1.010B | 16.50 |
| Teladoc Health (TDOC) | United States | $0.825B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $0.740B | 12.11 |
| Nutex Health (NUTX) | United States | $0.705B | 5.39 |
| Omada Health (OMDA) | United States | $0.655B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.641B | 0.00 |
| Embecta (EMBC) | United States | $0.602B | 3.36 |
| Enhabit (EHAB) | United States | $0.565B | 25.36 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.558B | 0.00 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.497B | 0.00 |
| SBC Medicals (SBC) | United States | $0.478B | 8.79 |
| CryoPort (CYRX) | United States | $0.418B | 0.00 |
| Strata Critical Medical (SRTA) | United States | $0.396B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.391B | 82.38 |
| Auna S.A (AUNA) | Luxembourg | $0.367B | 5.90 |
| So-Young (SY) | China | $0.328B | 0.00 |
| Shoulder Innovations (SI) | United States | $0.269B | 0.00 |
| Oncology Institute (TOI) | United States | $0.247B | 0.00 |
| Agilon Health (AGL) | United States | $0.150B | 0.00 |
| LifeMD (LFMD) | United States | $0.134B | 0.00 |
| Beauty Health (SKIN) | United States | $0.133B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.109B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.102B | 0.00 |
| Biodesix (BDSX) | United States | $0.091B | 0.00 |
| Park Dental Partners (PARK) | United States | $0.078B | 0.00 |
| DocGo (DCGO) | United States | $0.073B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.041B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.039B | 0.00 |
| Pomdoctor - (POM) | China | $0.026B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.018B | 5.62 |
| OSR Holdings (OSRH) | United States | $0.013B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.012B | 0.00 |
| Lifeward (LFWD) | United States | $0.009B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| XWELL (XWEL) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |